NCT00220389View on ClinicalTrials.gov

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2003

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Overactive Bladder
Interventions
DRUG

SPM 907

Trial Locations (1)

Unknown

Schwarz, RTP

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY